Company profile: Vico Therapeutics
1.1 - Company Overview
Company description
- Provider of RNA-modulating therapies for rare neurological/CNS disorders, focused on SCA, HD and RTT. Offers VO659, an antisense oligonucleotide targeting CAG repeat expansions in polyglutamine diseases (Spinocerebellar Ataxia types 1/3 and Huntington’s) to reduce mutant protein levels and improve motor function, and VICOMER, a platform designing RNA therapeutics via translation, splicing, editing, degradation and activation.
Products and services
- VICOMER RNA Modulating Platform: A modular antisense oligonucleotide engineering platform that architects RNA-targeting therapeutics by modulating translation, splicing, editing, degradation, and activation to correct specific genetic defects in CNS disorders
- VO659: A sequence-specific antisense oligonucleotide product candidate targeting CAG repeat expansions in SCA1, SCA3, and Huntington’s disease to reduce mutant protein levels and improve motor function
- CNS RNA Therapy Programs: An indication-focused discovery and development effort that delivers RNA modulating therapies for rare neurological disorders, initially concentrating on SCA, HD, and RTT across the central nervous system
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vico Therapeutics
Neuron Bio
HQ: Spain
Website
- Description: Provider of innovative biosolutions: AlzTEST blood biomarker diagnostic for Alzheimer’s; Omega-3 DHA microalgae oil for functional foods and nutraceuticals; MicroBiOil platform for microbial oils and oleochemicals; Microbiotools by Neol for bioprocess development; custom R&D in biomedicine, toxicology and agro-food; and a drug discovery platform for neurodegenerative diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neuron Bio company profile →
Lineagen
HQ: United States
Website
- Description: Provider of diagnostic and healthcare services for complex genetic diseases, offering FirstStepDx PLUS chromosomal microarray to identify genomic deletions/duplications associated with autism spectrum disorder, developmental delay, intellectual disability, congenital anomalies, dysmorphic features, and epilepsy; NextStepDx PLUS whole exome sequencing; genetic counseling; and optical genome mapping data services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lineagen company profile →
AlgoTx
HQ: France
Website
- Description: Provider of topical hydrogel therapies for complex pain, developing ATX01 to inhibit nociceptive sodium channels for targeted relief in chemotherapy-induced peripheral neuropathy and erythromelalgia, with plans to address additional peripheral neuropathic pain conditions such as painful diabetic peripheral neuropathy and phantom limb pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AlgoTx company profile →
Envoy Therapeutics
HQ: United States
Website
- Description: Provider of drug discovery focused on novel drugs for neurological and psychiatric diseases, using bacTRAP technology to identify proteins in vivo produced by specific cell types without isolating those cells, aiming for superior efficacy and fewer side effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Envoy Therapeutics company profile →
Precision Neuroscience
HQ: United States
Website
- Description: Provider of brain-computer interface technology, including the Layer 7 Cortical Interface, a minimally invasive, high-resolution implant for recording and stimulating brain activity; Precision BioMEMS microfabrication of biocompatible microelectrode arrays and foundry services; machine learning software to translate neural data; and a fast, reversible surgical implantation technique.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Precision Neuroscience company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vico Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vico Therapeutics
2.2 - Growth funds investing in similar companies to Vico Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vico Therapeutics
4.2 - Public trading comparable groups for Vico Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →